Spotlight Innovation

Spotlight Innovation targets healthcare technologies developed in American academic laboratories. The firm acquires or licenses early-stage IP and incubates the assets inside subsidiary companies. The website emphasizes a focus on university-originated medical research, though no specific university partnerships have been publicly named.

Celtic Biotech Iowa is a subsidiary of Spotlight Innovation Inc. It serves as the primary patent-holder and development vehicle for the firm's biological therapeutics program. In January 2015, Celtic Biotech Iowa was granted a patent by the U.S. Patent and Trademark Office, and in March 2015 it licensed a therapy targeting chronic kidney disease.

Spotlight Innovation is a public company trading on the OTCQB market under the ticker STLT. There is no disclosure of institutional fund commitments, limited partners, or private-capital raises. The firm's capital-access mechanism appears entirely through its publicly traded shares, which is atypical for venture-stage healthcare investing.

The firm targets preclinical and early-stage assets with unique intellectual property. Known portfolio activity involves patent-stage biological therapeutics and early pharmaceutical candidates. No evidence of revenue-stage or clinical-trial-stage investments has been disclosed in available records.

No philanthropic foundations, real-asset arms, operating businesses, or club memberships are publicly disclosed. Spotlight Innovation appears to operate solely through its parent entity and named subsidiaries, with no additional vehicles identified.